What May Have Driven Life Science Property Provider Ventas in Q2
Ventas (VTR) is slated to report its second-quarter results on July 27. Wall Street expects its results to be mixed, with revenue rising 1.6% YoY (year-over-year) to $910.2 million and AFFO (adjusted funds from operations) per share falling 2.9%. The segment is struggling with market oversupply, which is impacting its pricing power, average occupancy rate, and monthly REVPOR (revenue per occupied room).